Head to Head Comparison: Tarsus Pharmaceuticals (NASDAQ:TARS) versus Tilray Brands (NASDAQ:TLRY)

Tarsus Pharmaceuticals (NASDAQ:TARS) and Tilray Brands (NASDAQ:TLRY) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Insider & Institutional Ownership

90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 9.3% of Tilray Brands shares are held by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 0.8% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Tarsus Pharmaceuticals and Tilray Brands, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1	2	4	3	2.90
Tilray Brands	1	3	2	1	2.43

Tarsus Pharmaceuticals presently has a consensus price target of $90.50, suggesting a potential downside of 0.31%. Tilray Brands has a consensus price target of $8.00, suggesting a potential upside of 77.78%. Given Tilray Brands’ higher possible upside, analysts clearly believe Tilray Brands is more favorable than Tarsus Pharmaceuticals.

Valuation & Earnings

This table compares Tarsus Pharmaceuticals and Tilray Brands”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36 million	8.83	-$66.42 million	($1.09)	-83.28
Tilray Brands	$915.45 million	0.67	-$121.40 million	($1.08)	-4.17

Tarsus Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tilray Brands, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Tarsus Pharmaceuticals and Tilray Brands’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Tilray Brands	-13.11%	-7.76%	-5.59%

Risk and Volatility

Tarsus Pharmaceuticals has a beta of 0.54, meaning that its stock price is 46% less volatile than the S&P 500. Comparatively, Tilray Brands has a beta of 1.92, meaning that its stock price is 92% more volatile than the S&P 500.

Summary

Tarsus Pharmaceuticals beats Tilray Brands on 8 of the 15 factors compared between the two stocks.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

About Tilray Brands

Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.